Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2006

View Archived Issues

Anthrax antibody therapeutic Anthim completes phase I study

GSK and Pharmacopeia establish drug discovery and development alliance

Phase III study of CellCept in pemphigus vulgaris completes enrollment

CFD Therapeutics formed to advance novel cancer therapeutics

Pro-Pharmaceuticals advances phase II colorectal cancer trial of Davanat plus 5-FU

New series of KDR inhibitors presented by Amgen

Activity of pertuzumab evaluated in advanced ovarian cancer

Studies add to data on stem cell mobilization with AMD-3100

Phase I/II trial finds lenalidomide promising in recurrent epithelial ovarian cancer

Actavis reaffirms proposal to acquire Pliva

MediciNova begins phase I study for urinary incontinence treatment MN-246

Ispinesib fails to meet advancement criteria in platinum-sensitive NSCLC

Proteon Therapeutics raises funding to support development of PRT-201

NitroMed restructures R&D operations

Astellas changes Protopic label in Europe

Toyama and Astellas sign basic licensing agreement for T-3811 in Japan

Santen and Oakwood sign agreement on microsphere-based product for DME

Alfresa and Tanabe Seiyaku to comarket modafinil in Japan

Novel PAI-1 inhibitor from Wyeth presented with phase I studies for thrombosis ongoing

Ipilimumab studied in second-line metastatic melanoma patients

Results of study comparing Emisphere's oral heparin to injectable heparin

Novel agents for metabolic disorders reported in recent patents

Myozyme approved for Pompe disease in Europe

Serono seeks U.S., European approvals for new Rebif formulation

New agents for endocrine-related disorders imparted in recent patent literature

European approval for Erbitux in head and neck cancer

AEterna Zentaris presents preclinical data on ZEN-017, a novel tubulin and topo II inhibitor

VX-001 vaccine well tolerated and effective in phase I study in advanced cancer patients

EC-0225: A folate-targeted chemotherapeutic conjugate from Endocyte

Preclinical data behind ENMD-1198's IND approval presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...